Kevin J Whaley
Overview
Explore the profile of Kevin J Whaley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nador E, Mausser E, Marathe J, Politch J, Thurman A, Whaley K, et al.
Fertil Steril
. 2024 Oct;
123(3):534-536.
PMID: 39447830
No abstract available.
2.
Schaefer A, Yang B, Schroeder H, Harit D, Humphry M, Zeitlin L, et al.
Emerg Microbes Infect
. 2024 May;
13(1):2352520.
PMID: 38713593
Vaginal transmission from semen of male Ebola virus (EBOV) survivors has been implicated as a potential origin of Ebola virus disease (EVD) outbreaks. While EBOV in semen must traverse cervicovaginal...
3.
Zeitlin L, Cross R, Woolsey C, West B, Borisevich V, Agans K, et al.
Sci Transl Med
. 2024 Apr;
16(741):eadl2055.
PMID: 38569014
No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra virus (HeV) G glycoprotein,...
4.
Nador E, Xia C, Santangelo P, Whaley K, Costello C, Anderson D
Antibodies (Basel)
. 2024 Mar;
13(1).
PMID: 38534207
IgG Fc -glycosylation is necessary for effector functions and is an important component of quality control. The choice of antibody manufacturing platform has the potential to significantly influence the Fc...
5.
Abelson D, Barajas J, Stuart L, Kim D, Marimuthu A, Hu C, et al.
J Infect Dis
. 2023 Jul;
228(Suppl 7):S701-S711.
PMID: 37474248
Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development...
6.
Mausser E, Nador E, Politch J, Pauly M, Marathe J, Moench T, et al.
PLoS One
. 2023 Mar;
18(3):e0282147.
PMID: 36996137
High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use...
7.
Thurman A, Moench T, Hoke M, Politch J, Cabral H, Mausser E, et al.
Am J Obstet Gynecol
. 2023 Mar;
228(6):716.e1-716.e12.
PMID: 36870409
Background: With an unplanned pregnancy rate of 50% or more in many countries, there is an urgent need for contraceptives that are more accessible and acceptable. To meet the growing...
8.
Swope K, Morton J, Pogue G, Burden L, Partain N, Hume S, et al.
MAbs
. 2022 Jan;
14(1):2013594.
PMID: 35000569
The ongoing SARS-CoV-2 coronavirus pandemic of 2020-2021 underscores the need for manufacturing platforms that can rapidly produce monoclonal antibody (mAb) therapies. As reported here, a platform based on produced mAb...
9.
Shrestha B, Vincent K, Schaefer A, Zhu Y, Vargas G, Motamedi M, et al.
Proc Natl Acad Sci U S A
. 2021 Nov;
118(48).
PMID: 34815336
Nonhormonal products for on-demand contraception are a global health technology gap; this unmet need motivated us to pursue the use of sperm-binding monoclonal antibodies to enable effective on-demand contraception. Here,...
10.
Swope K, Morton J, Pogue G, Hume S, Pauly M, Shepherd J, et al.
Methods Enzymol
. 2021 Nov;
660:239-263.
PMID: 34742392
Monoclonal antibodies (mAbs) hold great promise for treating diseases ranging from cancer to infectious disease. Manufacture of mAbs is challenging, expensive, and time-consuming using mammalian systems. We describe detailed methods...